Highline Capital Management, L.P. Atara Biotherapeutics, Inc. Transaction History

Highline Capital Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$19.05 - $41.04 $5.28 Million - $11.4 Million	-277,183 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$28.4 - $41.74 $6.85 Million - $10.1 Million	-241,183 Reduced 46.53%	277,183 $11 Million
Q4 2018 Feb 14, 2019	BUY	$30.9 - $42.97 $8.99 Million - $12.5 Million	290,966 Added 127.95%	518,366 $18 Million
Q2 2018 Aug 14, 2018	BUY	$35.15 - $51.45 $7.99 Million - $11.7 Million	227,400 New	227,400 $8.36 Million

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.08B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Highline Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Highline Capital Management, L.P. with notifications on news.